Global single-use bioprocessing market projected to reach USD 100.9 billion by 2032
From GlobeNewswire: 2024-12-16 09:59:00
The global Single-Use Bioprocessing Market was valued at USD 26.8 billion in 2023, projected to reach USD 100.9 billion by 2032, growing at a CAGR of 15.9%. Demand for biologics and advanced therapies is fueling investments in single-use bioprocessing facilities. Governments are prioritizing biopharmaceutical manufacturing infrastructure development to meet the growing global demand. Single-use technologies are gaining prominence for their ability to reduce contamination risks, lower costs, and improve flexibility in biomanufacturing processes. The World Health Organization estimates the global biologics market will grow by 20% annually, with single-use bioprocessing technologies playing a crucial role in accelerating biologics production. Pfizer and Biocon Biologics have integrated single-use systems to scale up biologics manufacturing. Major players in the market include Thermo Fisher Scientific, Sartorius AG, Merck KGaA, and others. The single-use bioprocessing market report includes a market size analysis and segment breakdown by product, workflow, and end-use. The upstream bioprocessing segment accounts for the largest revenue share, with single-use bioreactors revolutionizing production scalability without complex equipment. Biopharmaceutical manufacturers dominate the market, utilizing single-use systems for efficient and cost-effective large-scale biologic production. The market is expected to witness transformative growth driven by the demand for biologics and advanced therapies. The Single-use Bioprocessing Market offers CDMOs the ability to scale operations rapidly and ensure compliance with regulatory standards. The market is segmented by product, workflow, and end-use, with North America leading in revenue share. Recent developments include Thermo Fisher Scientific and Cytiva launching new single-use technologies. Asia-Pacific is the fastest-growing market, driven by healthcare investments and biopharmaceutical manufacturing expansions.
Thermo Fisher Scientific and Cytiva have launched new single-use bioprocessing technologies to improve scalability and reduce process variability. In North America, the market is dominated by strong government support and leading players like Thermo Fisher Scientific and Danaher Corporation. In Asia-Pacific, countries like China and India are focusing on strengthening biopharma manufacturing capabilities through initiatives like “Made in China 2025” and “Pharma Vision 2025.”
The Single-use Bioprocessing Market is segmented by product, workflow, and end-use, with North America leading in revenue share. Recent developments include Thermo Fisher Scientific and Cytiva launching new single-use bioprocessing technologies. Asia-Pacific is the fastest-growing market, driven by healthcare investments and biopharmaceutical manufacturing expansions.
Thermo Fisher Scientific and Cytiva have launched new single-use bioprocessing technologies to improve scalability and reduce process variability. In North America, the market is dominated by strong government support and leading players like Thermo Fisher Scientific and Danaher Corporation. In Asia-Pacific, countries like China and India are focusing on strengthening biopharma manufacturing capabilities through initiatives like “Made in China 2025” and “Pharma Vision 2025.”
Read more at GlobeNewswire: Single-Use Bioprocessing Market Projected to Surpass USD